Bhimani, Jenna
O’Connell, Kelli
Ergas, Isaac J.
Foley, Marilyn
Gallagher, Grace B.
Griggs, Jennifer J.
Heon, Narre
Kolevska, Tatjana
Kotsurovskyy, Yuriy
Kroenke, Candyce H.
Laurent, Cecile. A.
Liu, Raymond
Nakata, Kanichi G.
Persaud, Sonia
Rivera, Donna R.
Roh, Janise M.
Tabatabai, Sara
Valice, Emily
Bowles, Erin J.A.
Bandera, Elisa V.
Kushi, Lawrence H.
Kantor, Elizabeth D.
Funding for this research was provided by:
National Cancer Institute (R50CA2111115, R37CA222793)
Geoffrey Beene Cancer Research Center
Article History
Received: 22 August 2023
Accepted: 11 April 2024
First Online: 13 June 2024
Declarations
:
: IRB approval was obtained from all sites involved in the study (Memorial Sloan Kettering Cancer Center, KPNC, KPWA, and Rutgers), with a waiver of consent to collect patient data at KPNC and KPWA.
: Not applicable.
: Dr. Bandera served as member of Pfizer’s Advisory Board to enhance minority participation in clinical trials (7/2021–8/2023). Dr. Liu served as member of Pfizer’s think tank think tank on real-world evidence sponsored by Pfizer on 11/28/23. Dr. Liu’s research funding (inst) unrelated to this current work: Genentech, AstraZeneca, Exact Sciences, Biotheranostics, and Beigene. Other authors have no COI to declare